Measles, mumps and rubella vaccine 12 months after hematopoietic stem cell transplantation.

Author: CostaSilvia Figueiredo, FernandesEder Gatti, HigashinoHermes Ryoiti, LopesMarta Heloisa, RandiBruno Azevedo, RochaVanderson Geraldo, SartoriAna Marli Christovam

Paper Details 
Original Abstract of the Article :
The measles, mumps and rubella (MMR) vaccine is usually recommended from 24 months after a hematopoietic stem cell transplant (HSCT). Some authors have demonstrated that the MMR vaccination can be safe from 12 months post-HSCT in non-immunosuppressed patients, as recommended by the Brazilian Nationa...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027056/

データ提供:米国国立医学図書館(NLM)

MMR Vaccine After Hematopoietic Stem Cell Transplantation

For patients who have undergone [hematopoietic stem cell transplantation (HSCT)], the [measles, mumps, and rubella (MMR) vaccine] is a critical part of their recovery. This study explores the safety of administering the MMR vaccine to patients at [12 months post-HSCT]. Imagine a desert oasis recovering after a long drought. This study explores how the MMR vaccine can help the oasis regain its strength and immunity after a major upheaval.

MMR Vaccination Safe From 12 Months Post-HSCT

The study found that [MMR vaccination] was [safe] for patients at [12 to 23 months post-HSCT]. The researchers found that MMR vaccination was safe for patients between 12 and 23 months after hematopoietic stem cell transplantation. This finding is encouraging, as it provides more flexibility in the vaccination schedule for these patients.

Safe and Timely Vaccination for HSCT Patients

The findings of this study contribute to the growing body of evidence supporting [safe and timely vaccination] for patients who have undergone [HSCT]. This research is like a camel caravan setting out across the desert. To ensure a safe and successful journey, the caravan needs to be properly prepared and protected. This study provides guidance on how to ensure that HSCT patients are adequately protected through timely and safe vaccination.

Dr.Camel's Conclusion

This study offers valuable insights into the safety of MMR vaccination in HSCT patients, providing reassurance for both patients and healthcare providers. It's like a desert oasis that is able to flourish thanks to a timely and effective irrigation system. This research contributes to the ongoing efforts to ensure that HSCT patients receive the best possible care.

Date :
  1. Date Completed 2023-03-24
  2. Date Revised 2023-03-24
Further Info :

Pubmed ID

36946817

DOI: Digital Object Identifier

PMC10027056

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.